Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06027840 · ClinicalTrials.gov registry record · Phase 1
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
A Phase 1 study of Smoking Cessation and Cigarette Smoking, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06027840 is a Phase 1 study of Smoking Cessation and Cigarette Smoking that is actively recruiting participants, run by Yale University. The registered enrollment target is 40 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06027840, a Phase 1 study of Smoking Cessation and Cigarette Smoking, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, counseling, and cessation resources (i.e., links to text-based support, self-change booklet). Varenicline helps to reduce cravings for tobacco use and decreases the pleasurable effects of cigarettes and other tobacco products.
Conditions Studied
Interventions
- DRUG Varenicline
- BEHAVIORAL Counseling
- BEHAVIORAL Guided Self-Change Booklets
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06027840
The ClinicalTrials.gov registry entry for NCT06027840 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (92% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Varenicline is the first listed.
NCT06027840 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06027840 about?
NCT06027840 is a clinical study titled "Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use". The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for q...
What is the current status of trial NCT06027840?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-04-01. Estimated completion is 2025-12.
What conditions does trial NCT06027840 study?
This clinical trial studies the following conditions: Smoking Cessation, Cigarette Smoking, E-cigarette Use.
What interventions are being tested in trial NCT06027840?
The interventions under investigation include: Varenicline (DRUG), Counseling (BEHAVIORAL), Guided Self-Change Booklets (BEHAVIORAL).
Who is sponsoring clinical trial NCT06027840?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06027840 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Overcoming Nicotine Dependence to Enable Quitting
RECRUITING · Phase 1
-
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
RECRUITING · Phase 1
-
Harnessing the Power of Technology: MOMBA for Postpartum Smoking
COMPLETED · Phase 1
-
Contingency Management, Quitting Smoking, and ADHD
COMPLETED · Phase 1
-
A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers
COMPLETED · Phase 1
-
Intervention for Support Persons to Help Smokers Quit
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.